The effect of trospium chloride on oesophageal motility.

abstract：BACKGROUND:Clearance of hepatitis B surface antigen (HBsAg) indicates clinical control of hepatitis B virus (HBV) infection. However, little is known about the impact of viral genomic variations on HBsAg loss. METHODS:We explored the association between viral genomic factors and HBsAg loss in 2121HBeAg-negative patien...

journal_title：Alimentary pharmacology & therapeutics

authors： Tseng TC,Liu CJ,Chen CL,Yang WT,Yang HC,Su TH,Wang CC,Kuo SF,Liu CH,Chen PJ,Chen DS,Kao JH

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:There is a need for effective and inexpensive therapy for Helicobacter pylori with good patient compliance. AIM:To evaluate a simplified twice daily schedule for treating H. pylori. METHODS:Patients infected with H. pylori (positive by CLO- and 13C-urea breath tests [UBT]) and not previously treated with a...

journal_title：Alimentary pharmacology & therapeutics

authors： Mönkemüller KE,Hirschowitz BI

更新日期：1999-05-01 00:00:00

abstract：BACKGROUND:The basis for individual variation in gastroduodenal vulnerability to NSAIDs is not well understood. AIM:To assess whether a gene expression signature is associated with susceptibility to gastroduodenal ulcerations. METHODS:Twenty-five Helicobacter pylori negative adults were treated for 7 days with naprox...

journal_title：Alimentary pharmacology & therapeutics

authors： Desai JC,Goo T,Fukata M,Sanyal S,Dikman A,Miller K,Cohen L,Brooks A,Wang Q,Abreu MT,Aisenberg J

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical trials. AIM:To assess the effectiveness and safety of OCA...

journal_title：Alimentary pharmacology & therapeutics

authors： Gomez E,Garcia Buey L,Molina E,Casado M,Conde I,Berenguer M,Jorquera F,Simón MA,Olveira A,Hernández-Guerra M,Mesquita M,Presa J,Costa-Moreira P,Macedo G,Arenas JI,Manuel Sousa J,Ampuero J,Morillas RM,Santos A,De Car

更新日期：2020-12-12 00:00:00

abstract：BACKGROUND:None of the proposed materials tested for the management of perianal fistulae has proven to be a definitive treatment. AIM:To assess a new repair scaffold and drug delivery device conceived to target perianal fistula repair. METHODS:Poly(D,L-lactide-co-glycolide) porous microspheres containing either antib...

journal_title：Alimentary pharmacology & therapeutics

authors： Blaker JJ,Pratten J,Ready D,Knowles JC,Forbes A,Day RM

更新日期：2008-09-01 00:00:00

abstract：BACKGROUND:Helicobacter pylori infection may persist after both first- and second-line current treatments. AIM:To assess the efficacy of a third-line, culture-guided treatment approach for the eradication of H. pylori. METHODS:Patterns of resistance were analysed in H. pylori isolates from 94 consecutive patients in ...

journal_title：Alimentary pharmacology & therapeutics

authors： Cammarota G,Martino A,Pirozzi G,Cianci R,Branca G,Nista EC,Cazzato A,Cannizzaro O,Miele L,Grieco A,Gasbarrini A,Gasbarrini G

更新日期：2004-04-01 00:00:00

abstract：BACKGROUND:H2-receptor antagonists are becoming widely available as over-the-counter medications for the treatment of heartburn and excess gastric acidity. AIM:To determine the effects of single low doses of ranitidine on intragastric acidity. METHODS:Intragastric pH was measured for 9 h after lunch in five studies i...

journal_title：Alimentary pharmacology & therapeutics

authors： Wyeth JW,Pounder RE,Sercombe JC,Snell CC

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND:Helicobacter pylori prevalence in Western countries has been declining simultaneously with increases in childhood asthma and allergic diseases; prior studies have linked these phenomena. AIMS:To examine the association between H. pylori colonisation in children and risk of asthma and related conditions at s...

journal_title：Alimentary pharmacology & therapeutics

authors： den Hollander WJ,Sonnenschein-van der Voort AM,Holster IL,de Jongste JC,Jaddoe VW,Hofman A,Perez-Perez GI,Moll HA,Blaser MJ,Duijts L,Kuipers EJ

更新日期：2016-04-01 00:00:00

abstract：BACKGROUND:Data on whether long-acting somatostatin analogue octreotide causes or prevents pancreatic injury following endoscopic retrograde cholangiopancreatography (ERCP) are controversial. AIM:This multicentre, prospective trial studied the effect of octreotide on pancreatic injury in a large unselected group of pa...

journal_title：Alimentary pharmacology & therapeutics

authors： Tulassay Z,Döbrönte Z,Prónai L,Zágoni T,Juhász L

更新日期：1998-11-01 00:00:00

abstract：BACKGROUND:Pancreatitis is a potentially severe condition. Patients with inflammatory bowel disease (IBD) seem to be at increased risk for acute pancreatitis. AIM:To describe the incidence, main causes and possible predictive factors of acute pancreatitis in inflammatory bowel disease. METHODS:Information was retrosp...

journal_title：Alimentary pharmacology & therapeutics

authors： Bermejo F,Lopez-Sanroman A,Taxonera C,Gisbert JP,Pérez-Calle JL,Vera I,Menchén L,Martín-Arranz MD,Opio V,Carneros JA,Van-Domselaar M,Mendoza JL,Luna M,López P,Calvo M,Algaba A

更新日期：2008-09-01 00:00:00

abstract：BACKGROUND:Both simple proportions and statistical tests are utilised for symptom-reflux association. We systematically compared three such tests in a clinical setting. AIM:To compare the three commonly used symptom reflux association tests in a large cohort of patients undergoing ambulatory pH monitoring for the eval...

journal_title：Alimentary pharmacology & therapeutics

authors： Kushnir VM,Sathyamurthy A,Drapekin J,Gaddam S,Sayuk GS,Gyawali CP

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Genetic polymorphisms in G-protein beta-3 subunit (GNβ3) and beta-2 adrenergic receptor (ADRB2) are associated with pain and gut hypersensitivity, which can overlap with gastroesophageal reflux disease (GERD). AIM:To evaluate relationships between single nucleotide polymorphisms (SNPs) within GNβ3 and ADRB2...

journal_title：Alimentary pharmacology & therapeutics

authors： Patel A,Hasak S,Nix BD,Sayuk GS,Newberry RD,Gyawali CP

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Although enteral nutrition is a recognized form of treatment for intestinal Crohn's disease, there are persisting problems with feed palatability and only limited data as to its mode of action. AIM:To assess the effects of a specific oral polymeric diet (CT3211; Nestle, Vevey, Switzerland), which is rich in...

journal_title：Alimentary pharmacology & therapeutics

authors： Fell JM,Paintin M,Arnaud-Battandier F,Beattie RM,Hollis A,Kitching P,Donnet-Hughes A,MacDonald TT,Walker-Smith JA

更新日期：2000-03-01 00:00:00

abstract：BACKGROUND:Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to thei...

journal_title：Alimentary pharmacology & therapeutics

authors： Joosse ME,Aardoom MA,Kemos P,Turner D,Wilson DC,Koletzko S,Martin-de-Carpi J,Fagerberg UL,Spray C,Tzivinikos C,Sladek M,Shaoul R,Roma-Giannikou E,Bronsky J,Serban DE,Ruemmele FM,Garnier-Lengline H,Veres G,Hojsak I,K

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Previous epidemiological studies suggest that patients diagnosed with nonalcoholic fatty liver disease (NAFLD) who drink light to moderate amounts of alcohol (up to ~30 g per day) have less severe histological lesions compared with nondrinkers. However, while the cross-sectional nature of current evidence pr...

journal_title：Alimentary pharmacology & therapeutics

authors： Sookoian S,Flichman D,Castaño GO,Pirola CJ

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:The threshold plasma paracetamol concentration at which N-acetylcysteine (NAC) treatment is recommended to treat paracetamol poisoning in a patient with induced liver enzymes (for example, with chronic liver disease or taking anticonvulsant drugs) is 50% lower than in a patient without induced liver enzymes....

journal_title：Alimentary pharmacology & therapeutics

authors： Jones AL,Jarvie DR,Simpson D,Hayes PC,Prescott LF

更新日期：1997-08-01 00:00:00

abstract：:Assessment of intragastric urease activity by the 13C-urea breath test was performed before and after one day of dosing with either De-Noltabs (tripotassium dicitrato bismuthate, one tablet 1 q.d.s.), Pepto-Bismol liquid (bismuth salicylate 30 ml q.d.s.), or Roter tablets (bismuth subnitrate, one tablet q.d.s.) in twe...

journal_title：Alimentary pharmacology & therapeutics

authors： Prewett EJ,Luk YW,Fraser AG,Lam WM,Pounder RE

更新日期：1992-02-01 00:00:00

abstract：BACKGROUND:Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exis...

journal_title：Alimentary pharmacology & therapeutics

authors： Lupascu A,Gabrielli M,Lauritano EC,Scarpellini E,Santoliquido A,Cammarota G,Flore R,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

更新日期：2005-12-01 00:00:00

abstract：BACKGROUND:The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules. METHODS:The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-neg...

journal_title：Alimentary pharmacology & therapeutics

authors： Müller P,Göksu MA,Fuchs W,Schlüter F,Simon B

更新日期：2000-09-01 00:00:00

abstract：BACKGROUND:Mitogen-activated protein (MAP) kinases, including extracellular signal-regulated kinases (ERK),c-Jun NH2-terminal kinases (JNK) and p38 MAP kinase (p38 MAPK) are important intermediates of the signal-transduction pathway from the cell surface to the nucleus. Expression of cyclooxygenase (COX)-2, associated ...

journal_title：Alimentary pharmacology & therapeutics

authors： Tominaga K,Higuchi K,Sasaki E,Suto R,Watanabe T,Fujiwara Y,Oshitani N,Matsumoto T,Kim S,Iwao H,Arakawa T

更新日期：2004-07-01 00:00:00

abstract：BACKGROUND:Patients with chronic hepatitis C virus and advanced fibrosis or cirrhosis are at risk for disease progression and hepatic decompensation. AIM:To determine the effects on hepatic histology of treatment with peginterferon alfa-2a (90 or 180 mug/week) or interferon alfa-2a (3 million units three times weekly)...

journal_title：Alimentary pharmacology & therapeutics

authors： Everson GT,Balart L,Lee SS,Reindollar RW,Shiffman ML,Minuk GY,Pockros PJ,Govindarajan S,Lentz E,Heathcote EJ

更新日期：2008-04-01 00:00:00

abstract：BACKGROUND:The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. AIM:To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids, metronidazole), with new aminosalicylates (4-aminosalicylic acid, balsa...

journal_title：Alimentary pharmacology & therapeutics

authors： Simmonds NJ,Millar AD,Blake DR,Rampton DS

更新日期：1999-03-01 00:00:00

abstract：BACKGROUND:The role of mesalazine in preventing the clinical recurrence of Crohn's disease after surgery has been shown in a meta-analysis of all published studies. No clear relationship, however, has been shown between dosage and response. AIM:To evaluate whether 4.0 g/day of mesalazine may offer therapeutic advantag...

journal_title：Alimentary pharmacology & therapeutics

authors： Caprilli R,Cottone M,Tonelli F,Sturniolo G,Castiglione F,Annese V,Papi C,Viscido A,Cammà C,Corrao G,Latella G

更新日期：2003-02-15 00:00:00

abstract：BACKGROUND:Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia. AIM:To assess utility of these markers in a Western population. METHODS:SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prev...

journal_title：Alimentary pharmacology & therapeutics

authors： Song M,Camargo MC,Weinstein SJ,Murphy G,Freedman ND,Koshiol J,Stolzenberg-Solomon RZ,Abnet CC,Männistö S,Albanes D,Rabkin CS

更新日期：2018-02-01 00:00:00

abstract：BACKGROUND:Gastro-oesophageal reflux disease (GERD) and irritable bowel syndrome may occur more often than expected by chance, but little community data exists and risk factors are unknown. AIM:To determine prevalence and risk factors for overlap of GERD and irritable bowel disease. METHODS:Population-based, cross-se...

journal_title：Alimentary pharmacology & therapeutics

authors： Jung HK,Halder S,McNally M,Locke GR 3rd,Schleck CD,Zinsmeister AR,Talley NJ

更新日期：2007-08-01 00:00:00

abstract：BACKGROUND:One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM:To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluo...

journal_title：Alimentary pharmacology & therapeutics

authors： Cammarota G,Cianci R,Cannizzaro O,Cuoco L,Pirozzi G,Gasbarrini A,Armuzzi A,Zocco MA,Santarelli L,Arancio F,Gasbarrini G

更新日期：2000-10-01 00:00:00

abstract：BACKGROUND:Budd-Chiari syndrome (BCS) is a rare but fatal disease caused by obstruction in the hepatic venous outflow tract. AIM:To provide an update of the pathophysiology, aetiology, diagnosis, management and follow-up of BCS. METHODS:Analysis of recent literature by using Medline, PubMed and EMBASE databases. RES...

journal_title：Alimentary pharmacology & therapeutics

authors： Khan F,Armstrong MJ,Mehrzad H,Chen F,Neil D,Brown R,Cain O,Tripathi D

更新日期：2019-04-01 00:00:00

abstract：:The study investigated the oral absorption of two antifungal agents, fluconazole and itraconazole, under conditions of low intragastric acidity. Twelve healthy male volunteers received each of 4 dosing regimens: 200 mg itraconazole alone, 200 mg itraconazole and famotidine, 100 mg fluconazole alone, and 100 mg flucona...

journal_title：Alimentary pharmacology & therapeutics

authors： Lim SG,Sawyerr AM,Hudson M,Sercombe J,Pounder RE

更新日期：1993-06-01 00:00:00

abstract：:In patients who present with chronic unexplained upper abdominal pain or discomfort (functional dyspepsia), therapy should ideally be targeted on correcting the individual's disturbed pathophysiology. Here, putative mechanisms implicated in functional dyspepsia and potential approaches to therapy are critically review...

journal_title：Alimentary pharmacology & therapeutics

authors： Talley NJ

更新日期：1995-04-01 00:00:00

abstract：AIM:To perform a systematic review on the efficacy of intermittent and on-demand therapy with either histamine H2-receptor antagonists or proton pump inhibitors for patients with erosive oesophagitis or symptomatic heartburn. METHOD:We conducted randomized-controlled trials of non-continuous therapy in gastro-oesophag...

journal_title：Alimentary pharmacology & therapeutics

authors： Zacny J,Zamakhshary M,Sketris I,Veldhuyzen van Zanten S

更新日期：2005-06-01 00:00:00